Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells

Oncology Reports

Volumn 13, Issue 3, 2005, Pages 477-483

  Kodani, Masahiro ^a   Igishi, Tadashi ^a   Matsumoto, Shingo ^a   Chikumi, Hiroki ^a   Shigeoka, Yasushi ^a   Nakanishi, Hirofumi ^a   Hashimoto, Kiyoshi ^a   Morita, Masato ^a   Yasuda, Kazuhito ^a   Hitsuda, Yutaka ^a   Shimizu, Eiji ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Akt; FK228; Histone deacetylase inhibitor; Sensitivity

Indexed keywords

AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIBIOTIC; DEPSIPEPTIDE; FR 901228; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE;

ADENOCARCINOMA; ARTICLE; BIOSYNTHESIS; CELL CULTURE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEPSIPEPTIDES; HUMANS; LUNG NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 15044343269     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.3.477     Document Type: Article

References (36)

1. Talapatra S and Thompson CB: Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther 298: 873-878, 2001. (Pubitemid 32761898)
2. Kiaris H and Spandidos DA: Mutations of ras acnes in human tumours (Review). Int J Oncol 7: 413-421, 1995.
3. Moodie SA, Willumsen BM, Weber MJ and Wolfman A: Complexes of Ras, GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260: 1658-1661, 1993. (Pubitemid 23247150)
4. Vojtek AB, Hollenberg SM and Cooper JA: Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74: 205-214, 1993. (Pubitemid 23219891)
5. Peyssonnaux C and Eychene A: The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93: 53-62, 2001. (Pubitemid 33040860)
6. Kelloff GJ, Lubet RA, Fay JR, Steele VE, Boone CW, Crowell JA and Sigman CC: Earnesyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prov 6: 267-282, 1997. (Pubitemid 27172892)
7. Kohl NE, Wilson PR, Mosser SD, Giuliani E, deSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP and Lee TJ: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141-9145, 1994.
8. Mross K, Steinbild S, Baas F, Reil M, Buss P, Mersmann S, Voliotis D, Schwartz B and Brendel E: Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. Int J Clin Pharmacol Ther 41: 618-619, 2003.
9. Richly H, Kupsch P, Passage K, Grubert M, Hilger RA, Kredtke S, Voliotis D, Scheulen ME, Seeber S and Strumberg D: A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int J Clin Pharmacol Ther 41: 620-621, 2003.
10. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
11. Datta SR, Brunet A and Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927, 1999.
12. Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene 22: 8983-8998, 2003. (Pubitemid 38121699)
13. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A and Loeffler JS: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22: 1926-1933, 2004. (Pubitemid 41095185)
14. Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS and Shepherd FA: Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 9: 2241-2247, 2003. (Pubitemid 36687649)
15. Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997, 2001. (Pubitemid 32720961)
16. Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T and Mutoh S: Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 64: 1079-1090, 2002. (Pubitemid 35247815)
17. Kosugi H, Ito M, Yamamoto Y, Towatari M, Ueda R, Saito H and Naoe T: In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocyte leukemia in NOD/Shi-scid/ scid mice. Jpn J Cancer Res 92: 529-536, 2001. (Pubitemid 32515094)
18. Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ and Hawkins MJ: A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2: 325-332, 2002. (Pubitemid 35265981)
19. Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216, 2000. (Pubitemid 30627729)
20. Rajgolikar G, Chan KK and Wang HC: Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res Treat 51: 29-38, 1998. (Pubitemid 28550158)
21. Fecteau KA, Mei J and Wang HC: Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228. J Pharmacol Exp Ther 300: 890-899, 2002. (Pubitemid 34164993)
22. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA and Schrump DS: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94: 504-513, 2002. (Pubitemid 34411289)
23. Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8: S55-61, 2002.
24. Sato S, Fujita N and Tsuruo T: Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97: 10832-10837, 2000.
25. Hostein I, Robertson D, DiStefano F, Workman P and Clarke PA: Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61: 4003-4009, 2001. (Pubitemid 32720963)
26. Steel GG and Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91, 1979. (Pubitemid 9120186)
27. Nakashio A, Fujita N, Rokudai S, Sato S and Tsuruo T: Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 60: 5303-5309, 2000.
28. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P and Hemminas BA: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15: 6541-6551, 1996. (Pubitemid 26413787)
29. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789, 1995. (Pubitemid 26004411)
30. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
31. Sato S, Fujita N and Tsuruo T: Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21: 1727-1738, 2002. (Pubitemid 34259036)
32. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L and Khuri FR: Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8: 1178-1184, 2002. (Pubitemid 34517656)
33. Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba, II, Milchgrub S, Brezinschek R, Virmani A, Gazdar AF and Minna JD: Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 17: 1557-1565, 1998. (Pubitemid 28472760)
34. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R and Bates SE: Inhibitor of histone dcacetylalion, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865-2868, 2001.
35. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP and Bates SE: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718-728, 2002. (Pubitemid 34742100)
36. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ and Chen CS: 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64: 1444-1451, 2004. (Pubitemid 38235615)